• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiation Protection Dosimetry >Beta Radiation Exposure Of Staff During And After Therapies With ~(90)y-labelled Substances
【24h】

Beta Radiation Exposure Of Staff During And After Therapies With ~(90)y-labelled Substances

机译：〜（90）y标记物质在治疗期间和之后的工作人员Beta辐射暴露

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Radioimmunotherapies (RITs) and peptide receptor radiotherapies (PRRTs) with ~(90)Y-labelled compounds offer promising prospects for tumor treatment in nuclear medicine. However, when preparing and performing these therapies, which require manipulations of high activities of ~(90)Y (>1 GBq), technicians and physicians may receive high exposures, mainly to the skin of the hands. Even non-occupationally exposed persons, such as caregivers and family members, receive external exposures in the initial period after therapy, arising from the ~(90)Y in the patient. The local skin doses of the individual staff members, measured during RITs and PRRTs with thermoluminescence detectors fixed with tapes to the fingers, vary considerably. The exposure of staff can exceed the annual permissible dose limit of 500 mSv if radiation protection standards are low. Thus, adequate safety measures are needed. Measurements of the dose rate around patients, made using survey meters with sufficient response to beta particles, indicate that the exposure of caregivers and family members is considerably higher than previously assumed, and was dominated by primary beta radiation instead of bremsstrahlung. Nevertheless, under normal circumstances, the annual dose limits for the public (effective dose: 1 mSv, skin dose: 50 mSv) will be complied with.
机译：带有〜（90）Y标记化合物的放射免疫疗法（RITs）和肽受体放射疗法（PRRT）为核医学中的肿瘤治疗提供了有希望的前景。但是，在准备和执行这些治疗时，需要对〜（90）Y（> 1 GBq）的高活性进行操作，技术人员和医师可能会暴露在高剂量下，主要是手的皮肤。即使是非职业接触者，例如护理人员和家庭成员，在治疗后的最初阶段也会因患者的〜（90）Y而接受外部接触。在RIT和PRRT期间使用带胶带固定在手指上的热发光检测器测量的各个工作人员的局部皮肤剂量变化很大。如果辐射防护标准很低，工作人员的暴露量可能会超过500 mSv的年度允许剂量限值。因此，需要足够的安全措施。使用对β粒子有足够反应的测量仪对患者周围的剂量率进行测量，结果表明护理人员及其家庭成员的暴露水平大大高于先前的假设，并且主要由β辐射而不是bre致辐射所致。但是，在正常情况下，将符合公众的年度剂量限制（有效剂量：1 mSv，皮肤剂量：50 mSv）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号